Drug Trial Radar · NCT03772223
A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.
Last checked: Nov 19, 2026Latest source record: May 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Jan 21, 2019
Primary completion
May 10, 2019
Study completion May 10, 2019
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 study to compare the pharmacokinetics of budesonide and albuterol delivered by PT027 compared with PT007 and PT008 administered separately.
Conditions
- Healthy Volunteers
Interventions
Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)Drug
Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
Treatment B (Budesonide metered dose inhaler)Drug
Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
Treatment C (Albuterol Sulfate metered dose inhaler)Drug
Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC for albuterolTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
- AUC for budesonideTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
- AUC(0-t) for albuterolTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
- AUC(0-t) for budesonideTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
- Cmax for albuterolTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
- Cmax for budesonideTime frame: At Day 1 (pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose), and Day 2 (24 hours post dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.